Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas

References

• Gatter K C, Warnke R A. Diffuse large B-cell lymphoma. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, Lyon 2001; 171–174
   Google Scholar
• Lossos I S. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6351–6357
   PubMed Web of Science ®Google Scholar
• Horsman D. Cytogenetic analysis of malignant lymphoma. The lymphomas. 2nd ed, G P Canellos, T A Lister, B Young. Saunders Elsevier, Philadelphia, PA 2006; 39–62
   Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B-cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
   PubMed Web of Science ®Google Scholar
• Staudt L M. Molecular diagnosis of the lymphomas by gene expression profiling. The lymphomas. 2nd ed, G P Canellos, T A Lister, B Young. Saunders Elsevier, Philadelphia, PA 2006; 110–126
   Google Scholar
• Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387–6393
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Fisher R I. Large-cell lymphoma: nodal, splenic. The lymphomas. 2nd ed, G P Canellos, T A Lister, B Young. Saunders Elsevier, Philadelphia, PA 2006; 295–324
   Google Scholar
• Sanchez-Beato M, Sanchez-Aguilera A, Piris M A. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101: 1220–1235
   PubMed Web of Science ®Google Scholar
• Fischer P M, Gianella-Borradori A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2003; 12: 955–970
   PubMed Web of Science ®Google Scholar
• Meijer L, Borgne A, Mulner O, Chong J P, Blow J J, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527–536
   PubMedGoogle Scholar
• McClue S J, Blake D, Clarke R, Cowan A, Cummings L, Fischer P M, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102: 463–468
   PubMed Web of Science ®Google Scholar
• Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16: 1169–1176
   PubMed Web of Science ®Google Scholar
• Alvi A J, Austen B, Weston V J, Fegan C, Maccallum D, Gianella-Borradori A, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by downregulation of genes involved in transcription regulation and survival. Blood 2005; 105: 4484–4491
   PubMed Web of Science ®Google Scholar
• MacCallum D E, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005; 65: 5399–5407
   PubMed Web of Science ®Google Scholar
• Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042–1047
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans H C, Limpens J, Meerabux J, Beverstock G C, Jansen J H, de Jong D, et al. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia 1991; 5: 221–224
   PubMed Web of Science ®Google Scholar
• Dyer M J, Fischer P, Nacheva E, Labastide W, Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4;11) chromosomal translocations. Blood 1990; 75: 709–714
   PubMed Web of Science ®Google Scholar
• Tweeddale M E, Lim B, Jamal N, Robinson J, Zalcberg J, Lockwood G, et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 1987; 69: 1307–1314
   PubMed Web of Science ®Google Scholar
• Nagai M, Fujita M, Ohmori M, Matsubara S, Taniwaki M, Horiike S, et al. Establishment of a novel human B-cell line (OZ) with t(14;18)(q32;q21) and aberrant p53 expression was associated with the homozygous deletions of p15INK4B and p16INK4A genes. Hematol Oncol 1997; 15: 109–119
   PubMed Web of Science ®Google Scholar
• Bernardin F, Collyn-d'Hooghe M, Quief S, Bastard C, Leprince D, Kerckaert J P. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation. Oncogene 1997; 14: 849–855
   PubMed Web of Science ®Google Scholar
• Chang H, Blondal J A, Benchimol S, Minden M D, Messner H A. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma 1995; 19: 165–171
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martini V, et al. Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006; 132: 303–316
   PubMed Web of Science ®Google Scholar
• Corcione A, Arduino N, Ferretti E, Raffaghello L, Roncella S, Rossi D, et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res 2004; 10: 964–971
   PubMed Web of Science ®Google Scholar
• Troester M A, Hoadley K A, Sorlie T, Herbert B S, Borresen-Dale A L, Lonning P E, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64: 4218–4226
   PubMed Web of Science ®Google Scholar
• Senderowicz A M, Sausville E A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376–387
   PubMed Web of Science ®Google Scholar
• Lam L T, Pickeral O K, Peng A C, Rosenwald A, Hurt E M, Giltnane J M, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001; 2: RESEARCH0041
   PubMed Web of Science ®Google Scholar
• Jiang J, Matranga C B, Cai D, Latham V M, Jr, Zhang X, Lowell A M, et al. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 2003; 63: 7410–7422
   PubMed Web of Science ®Google Scholar
• Ma Y, Cress W D, Haura E B. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003; 2: 73–81
   PubMed Web of Science ®Google Scholar
• Ma Y, Freeman S N, Cress W D. E2F4 deficiency promotes drug-induced apoptosis. Cancer Biol Ther 2004; 3: 1262–1269
   PubMed Web of Science ®Google Scholar
• Mihara M, Shintani S, Kiyota A, Matsumura T, Wong D T. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int J Oncol 2002; 21: 95–101
   PubMed Web of Science ®Google Scholar
• Hahntow I N, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18: 747–755
   PubMed Web of Science ®Google Scholar
• Tirado O M, Mateo-Lozano S, Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 2005; 65: 9320–9327
   PubMed Web of Science ®Google Scholar
• Raynaud F I, Whittaker S R, Fischer P M, McClue S, Walton M I, Barrie S E, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005; 11: 4875–4887
   PubMed Web of Science ®Google Scholar
• Mohapatra S, Chu B, Zhao X, Pledger W J. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65: 7717–7723
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 2005; 4: 113–124
   PubMed Web of Science ®Google Scholar
• Cai D, Byth K F, Shapiro G I. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 2006; 66: 435–444
   PubMed Web of Science ®Google Scholar
• Farrugia M M, Duan L J, Reis M D, Ngan B Y, Berinstein N L. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. Blood 1994; 83: 191–198
   PubMed Web of Science ®Google Scholar
• Phan R T, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635–639
   PubMed Web of Science ®Google Scholar
• Drexler H G. Guide to leukemia-lymphoma cell lines. DSMZ, BraunschweigGermany 2005
   Google Scholar
• Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, et al. Comparative genome wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol 2006; 134: 27–36
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar